|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 68.26 BRL | +2.93% |
|
+2.34% | +3.49% |
| 24/07 | Amgen submits new data to challenge FDA's proposal to withdraw Tavneos | RE |
| 24/07 | CuraTeQ Biologics Wins European Medicines Agency's Positive Opinion for Neulasta Biosimilar | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- AMGN Stock
- AMGN34 Stock
- Consensus Amgen Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
